QCDR Measure:
AAO-10: Exudative Age-Related Macular Degeneration: Loss of Visual Acuity

National Quality Strategy Domain:
Effective Clinical Care

Measure Type:
Outcome

Description:
Percentage of patients with a diagnosis of exudative age-related macular degeneration, being treated with anti-VEGF agents, with of loss of less than 0.3 logMar of visual acuity within the past 12 months.

Instructions:
This measure is to be reported a minimum of once per reporting period for patients seen during the reporting period. It is anticipated that clinicians who provide the primary management of patients with exudative age-related macular degeneration (in either one or both eyes) will submit this measure.

Denominator:
All patients aged 18 years or older with a diagnosis of exudative age-related macular degeneration and documentation of laterality (OD, OS, OU)

Denominator Criteria

Patients aged ≥ 18 years

AND

Diagnosis of Exudative Age-Related Macular Degeneration

- Exudative age-related macular degeneration (ICD-10: H35.32)

AND

Four or more recorded visual acuity values in the past 12 months

AND

Treatment with Anti-VEGF Agents

- Ranibizumab (Lucentis®) injections (CPT: 67028 & HCPCS: J2778)
• Aflibercept (EYLEA®) injections (CPT: 67028 & HCPCS: J0178)

**Numerator:**

Patients with four or more recorded visual acuity values within the past 12 months; loss of visual acuity less than 0.3 logMar. Visual acuity of the eye(s) being treated will be evaluated.

**Numerator Options:**

- **Performance Met:** Patients who achieved a loss in visual acuity of \( \leq 0.3\) logMar
- **Performance Not Met:** Patients who did not achieve a loss in visual acuity of \( \leq 0.3\) logMar

**Improvement Notation:**

Higher score indicates better performance